Henoch-Schonlein Purpura
Conditions
Interventions
HSP of treatment-naive (Group A):Antibiotics (Amoxicillin/Clavulanate or oral azithromycin )
HSP of treatment-naive (Group A):Glucocorticoid (Prednisone)
HSP of treatment-naive (Group A):Heparin
HSP of treatment-naive (Group A):Chinese patent drug (Safflower Yellow injection)
HSP of treatment-naive (Group A):Vitamin C
HSP of treatment-naive (Group A):Omeprazole
HSP of treatment-naive (Group A) :Ganciclovir
Sponsors
The First Affiliated Hospital of Kunming Medical University
Eligibility
Sex/Gender
All
Age
3 Years to 14 Years
Inclusion criteria
Inclusion criteria: Between May 2014 and March 2015, 96 children who were between 4 to 16 years old were diagnosed with HSP in the Department of Pediatrics, the First Affiliated Hospital of Kunming Medical University. Among them, 33 subjects were recruited for the clinical study based on the following inclusion criteria (Figure S1): under 18 years of age; presence of two or more additional HSP-indicative symptoms (e.g., gastrointestinal, joint, and kidney symptoms) besides cutaneous lesion; no prior treatment for HSP; no administration of antibiotics within latest 2 months prior to entry. All the HSP subjects received the treatment that lasted between 5 to 21 days. For whole-metagenomic analyses, 10 individuals were randomly selected from the 33 HSP patients along with 9 healthy controls with comparable ages, body weight, and gender ratio. This study was approved by the Ethics Committee of Kunming Medical University. Signed informed consent was obtained from the guardians of all participants upon their enrollment. All procedures were conducted in compliance with the Declaration of Helsinki.
Exclusion criteria
Exclusion criteria: 1. There are less than 3 clinical symptoms of Henoch Schonlein purpura; 2. Outpatients; 3. Patients who are unable to take stool samples after admission or before discharge; 4. Patients who are participating in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Routine blood test;D-Dimer;Fibrinogen degradation products (FDP);Urine protein;Urinary Red Cells;C-reactive protein;Erythrocyte sedimentation rate;Immunoglobulin A;Fecal occult blood;Species analysis of fecal microorganism; | — |
Countries
China
Contacts
Public ContactYongkun Huang
The First Affiliated Hospital of Kunming Medical University
Outcome results
None listed